Nefromedica - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 129,303 | 125,676 | 128,911 | 102,902 | 120,090 | 181,962 | 210,527 | 130,198 |
| Profit before tax | - | 25,221 | 26,448 | 1,190 | 12,730 | 67,504 | 78,381 | 7,862 |
| Net profit | 27,813 | 25,221 | 26,142 | 1,190 | 12,730 | 67,504 | 78,381 | 7,390 |
| Equity | 46,368 | 71,589 | 97,731 | 98,921 | 61,651 | 104,154 | 123,712 | 72,278 |
| Liabilities | 6,018 | 7,585 | 6,348 | 6,591 | 9,530 | 8,180 | 6,361 | 6,917 |
| Non-current assets | 248 | 133 | 18 | 8 | 8 | 282 | 156 | 30 |
| Current assets | 51,518 | 78,579 | 103,765 | 105,232 | 70,877 | 111,465 | 129,424 | 78,687 |
| Total assets | 51,766 | 78,712 | 103,783 | 105,240 | 70,885 | 111,747 | 129,580 | 78,717 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 16,832 | 24,828 | 23,432 |
| Social insurance contributions | - | - | - | - | - | 17,070 | 20,619 | 19,005 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -19.0% | -2.8% | +2.6% | -20.2% | +16.7% | +51.5% | +15.7% | -38.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 53.7% | 32.0% | 25.2% | 1.1% | 18.0% | 60.4% | 60.5% | 9.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 60.0% | 35.2% | 26.7% | 1.2% | 20.6% | 64.8% | 63.4% | 10.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 21.5% | 20.1% | 20.3% | 1.2% | 10.6% | 37.1% | 37.2% | 5.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 20.1% | 20.5% | 1.2% | 10.6% | 37.1% | 37.2% | 6.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 18,472 | 17,954 | 18,199 | 14,032 | 17,156 | 25,390 | 27,165 | 16,275 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nefromedica - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-09-16 | 2025-09-21 | 19.77 |
Nefromedica - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Nefromedica, UAB (code 300609641) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of €130.2K and net profit of €7.4K, with a profit margin of 5.7%. Performance weakened compared with 2024, when revenue reached €210.5K and net profit was €78.4K, after 2023 revenue of €182.0K and net profit of €67.5K. This shows a strong profit level in 2023-2024 followed by a notable slowdown in 2025. The latest year also shows revenue down 38.2% year on year and down 28.4% over two years. At year-end 2025, total assets were €78.7K, equity €72.3K and liabilities €6.9K, indicating a high equity ratio of 91.8% and low leverage, with debt-to-equity at 0.10. Asset turnover was 1.65x, ROE 10.2% and ROA 9.4%. Revenue per employee was €16.3K, while profit per employee was €924, reflecting the weaker 2025 operating result.